Validation of EORTC QLQ-LC43 for Chinese patients with lung cancer
Lei Zhang(Wenzhou Medical University), Changli Wang(Tianjin Medical University Cancer Institute and Hospital), Wei‐Dong Lü(Shaanxi Provincial People's Hospital), Stephanie Woo(Harvard University Press), Jing Zhang(Capital Medical University), Le Luo(Central South University), Chong Pang(Tianjin Medical University Cancer Institute and Hospital), Lin Yue(Tianjin Medical University Cancer Institute and Hospital), Hong Zhu(Tianjin Medical University), Weiran Liu(Tianjin Medical University Cancer Institute and Hospital), Adam R. Miller(Indiana University School of Medicine), Yanjun Su(Tianjin Medical University Cancer Institute and Hospital), Yanni Hua(Tianjin Medical University), Jinglian Wu(Tianjin Medical University Cancer Institute and Hospital), Shumin Xie(South China Agricultural University)
Cited by 15
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Porphyromonas gingivalis lipopolysaccharide induces cognitive dysfunction, mediated by neuronal inflammation via activation of the TLR4 signaling pathway in C57BL/6 mice
|Journal of Neuroinflammation|2018|299
Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota
|Nature Metabolism|2024|205
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
|Molecular Cancer|2023|194
Atomic ruthenium doping in collaboration with oxygen vacancy engineering boosts the hydrogen evolution reaction by optimizing H absorption
|Chemical Engineering Journal|2023|142